CANCER'S CAUSE, CANCER'S CURE (18 page)

After uncovering the restorative effects of RNA fragments
in vivo
, the microbiologist teamed up with several M.D.s who administered the fragments to people with cancer. The RNA fragments behaved the same in humans as they did
in vivo
, protecting patients receiving radiation therapy and intensive chemotherapy. This was a new beneficial situation which worked well, provided that human patients received enough RNA primers early in their conventional treatments. Beljanski found the primers need to be ingested before all of the cancer patient’s bone marrow stem cells are destroyed by chemotherapeutic poisons.

However, the evidence is clear: RNA fragments, priming only healthy cells, are powerful healing agents. The other rare cases where RNA fragments show no effect against the side effects of cancer are either when there is a lack of hemoglobin (in red blood cells which number less than 2.5 million) or when there is an excess of ribonuclease in the blood (ribonuclease is an important enzyme that breaks down RNA into smaller components in part to help the body get rid of excess RNA), which may be partially inhibited by the ingestion of magnesium. An excess in ferritin (a mineral component in which iron is linked to a protein) can also slow down RNA fragment activity.

Recent Clinical Trials of RNA Fragments

Dr. Michael Schachter firmly believes that cancer victims and other people receiving chemotherapy could benefit from taking RNA fragments.
There are some pioneers in cancer research who believe as Dr. Schachter does and are taking the study of RNA fragments a step further by initiating clinical trials as the means to instill confidence in this non-toxic but experimental approach. In early 2005, a Phase I clinical trial focusing on RNA fragments was initiated at the Cancer Treatment Centers of America (CTCA). The Center’s trial was titled “Study on the role of an RNA-fragment-based dietary supplement in the maintenance of white blood cell production during chemotherapy.” The chemotherapy protocol these patients underwent was extremely heavy, and they were particularly at risk of hemorrhage following the loss of their platelets.

By using RNA-fragments, patients in the CTCA clinical trial avoided such risks. Further clinical trials began again in January of 2008. In 2010, Drs. Levin, Daehler, Grutsch, Hall, Gupta, and Lis reported the findings of those trials. The trials were conducted as an onsite study at the Cancer Treatment Centers of America at Midwestern Regional Medical Center in Zion, Illinois. Thirty-two patients underwent a clinical trial using these RNA fragments of the
E. coli
bacteria. Forty different patients signed a consent form to participate in a separate trial using RNA fragments derived from yeast. The trial was set up to study platelet counts in patients who had varying degrees of exposure to chemotherapy to see which RNA fragments—the yeast-derived or the
E coli
-derived— were more effective. Twenty-four of the patients had in fact previously failed between one to nine prior regiments.

The results of the study were striking. The researchers state, “The primary goal of anti-chemotherapy induced thrombocytopenia (when platelets are lost from the bloodstream faster than they can be replaced) is the avoidance of delays in treatment and reductions in the dose of chemotherapy. Four patients experienced a treatment delay or reduction in chemotherapy dosage in the yeast-fragment arm of the trial, but
no
patient using
E. coli
RNA fragments had an unplanned dose reduction or delay” (proving that not all RNA fragments are created equal). They further state that at the higher dosage level of sixty or eighty milligrams of the
E. coli
RNA fragments, there were no platelet transfusions required.

The researchers conclude that “at all doses, patients receiving
E. coli
RNA fragments showed a recovery in platelet numbers of 80,000/ml by the end of eight days following chemotherapy nadir (the low point of the platelet count)” and, given the data found in the study, the CTCA plans “further clinical trials designed to measure the efficacy of
E. coli
RNA fragments in the management of Chemotherapy-induced Thrombocytopenia (CIT) among patients with advanced cancer.”

Similar comments to those of the CTCA were made by Maurice Stroun, Ph.D., Professor of Biochemistry at Switzerland’s University of Geneva. I conducted a one-on-one tape-recorded interview of Dr. Stroun in Paris when he visited with me on September 6, 2003. Dr. Stroun enthusiastically praised the anticancer research of Mirko Beljanski. As part of his statement, he made some personal remarks.

Among them he said:

“Right now, there’s only one real supplement for the adverse effects of chemotherapy and radiation therapy, and that’s RNA fragments. I have a friend who recently had a serious case of leukemia…thanks to the RNA fragments, he was able to request heavier chemotherapy than is normally given and to significantly increase his chances of survival. The product definitely has that effect. And the fact that it doesn’t have any side effects—that’s what’s really fantastic!”

Dr. James F. Grutsch has provided the definitive word on the utter applicability of these RNA fragments: he considers this “concentrated source” of RNA a “food.” He states, “RNA fragments can be essential nutrients…Every time you eat salads or meat, you are eating RNA.” He adds that while other products proclaim to maintain healthy platelet counts, “they do not. There is something about what Beljanski specifically uncovered that is completely unique.”
RNA fragments are practically always active. Because of their specific action on bone marrow, they make it possible to see a rise in white blood cell and platelet blood count levels within forty-eight hours. The stability, user-friendliness and effectiveness of RNA fragments are, indeed, physiologically remarkable.

Moreover, the idea behind the creation of RNA fragments was completely original. It opens the door to new perspectives on the selective activation of certain genes, which could lead to a completely novel therapeutic approach to cancer. The fact that they are not transcribed in DNA, that they only prime or prepare one’s physiology for a single action, and that afterwards they are broken down and eliminated by plasma nucleases, all create a powerful argument in favor of their safety.

I have already emphasized in terms of the anticancer molecules from Pao pereira and
Rauwolfia vomitoria
that
selectivity
is an idea which should be the cornerstone for the next generation of non-toxic and natural therapeutic products from plants, from microorganisms, and/or from animals. This development of
E. coli
RNA fragments represents one of Dr. Mirko Beljanski’s greatest conceptual advancements, and it should stand as a cornerstone in integrative cancer therapies now and in the future.

Ginkgo biloba
—Integrative Approach #3

Up to this point, we have talked mostly about chemotherapy and the toxic side effects it has on the human body. I have mentioned radiotherapy throughout, but have not addressed it directly up until this point. Radiation treatment has long been used to fight cancer. It is supposed to shrink tumors by killing the cancer cells.

Radiation is also a known carcinogen. People everywhere are talking about radiation and the danger X-rays, high tension wires, computer screens, microwaves, mammographies, scans, airport screens, cell phones, iPhones, and the myriad of other electronic devices we’re attached to practically all the time. Such conveniences unquestionably pose dangers to our chromosomes. They are a main underlying source of the increase in cancer found in every population in the civilized world.

Radiation exposes all persons to measurable and immeasurable harm. Several highly critical articles, written by specialists on these issues, can be found on the internet. For example, J.W. Gofman, Ph.D., Professor Emeritus of Molecular and Cellular Biology at the University of California, Berkeley—not one to talk about a subject of which he is unaware—led a massive investigation involving scientists, doctors, etiologists (the scientists who study the origins and causes of disease) and physicians. The investigation was published in November 1999. The investigators concluded, in print, some crystal-clear truths. According to Dr. Gofman’s research, medical radiation, introduced as a treatment in 1896, is becoming a factor in approximately half of all fatal cases of cancer in the U.S. The proof cited in his 1999 monograph, which no one has refuted, indicates that approximately two-hundred fifty thousand people in the U.S. die prematurely each year from cancer and coronary diseases, with half the cases due to the unnecessary and excessive use of X-rays that they received over a lifetime.

The warning is clear: minimize or avoid any exposure to X-rays of any kind. Radiation due to medical imaging is the underlying causative factor in approximately half of the fatalities in the treatment of coronary diseases in the U.S. Also, with the inappropriate use of CT Scans, MRIs, SPECT Scans, and other forms of medical imaging, danger lies waiting in everyone’s future. Due to concern for profitability, negligence, and lack of coordination, medical imaging is overused and is administered at excessive doses. Remember, I am still only talking about medical imaging, to say nothing of therapeutic radiation treatments for cancer. Since risks associated with radiation are cumulative and proportional to accumulated doses of X-rays, one should (and can) insist that our doctors and radiologists reduce by half regular doses administered in radiation therapy, scans, fluoroscopes, etc. In other words, beware of diagnostic X-rays.

Dangers from Diagnostic Radiation and Radiotherapy

It is well known that some of the conventional oncological treatments, particularly radiation therapy, can induce DNA mutations, fibrosis, or smoldering skin burns. The lowered immunity in scar tissue predisposes it to what’s called malignant degeneration, the transformation of a benign lesion anywhere in the body into a malignant one. According to research oncologist, Dr. E. B. Kaplan: “There is an elevated mortality rate: one out of three or four patients with burns or osteomyelitis (a bone infection), or irradiated cancer dies from dermatological complications.”

The dangers to which I am referring relate to both diagnostic radiation and radiotherapy. They fall into two categories of damage to human beings:

a. DNA breakages and mutations

b. Alteration in the DNA’s secondary structure (DNA destabilization)

A main goal in Dr. Mirko Beljanski’s research, which was evidenced in the improvement experienced by patients undergoing chemotherapy, radiation therapy, and other harsh treatments, was prevention of unhealthy cell multiplication. His major goal, always, was to improve a patient’s chances for homeostasis, the ideal state of the body by which all systems maintain a stable, constant condition.

You have just read about the ability of RNA fragments to handle dangerously low white blood cell and platelet counts. Dr. Mirko Beljanski and his team also discovered in the late 1970s that a particular variation of the leaf from the
Ginkgo biloba
tree can be used to handle the myriad of side effects of radiation (as well as surgery) including burns, fibrosis, and the normalization of abnormal proteins.

Studies in Radiation Poisoning

On March 17, 1978, Dr. Mirko Beljanski and his wife were no longer allowed access to the laboratories at the Pasteur Institute. As I reported in the previous chapter, upon expulsion from the Pasteur, they found a new home for their microbiological investigations at France’s Chotenay- Malabry School of Pharmacy.
There, the Beljanskis were awarded the six-year contract with the French army I mentioned above to study phenomena involved in protecting against radiation. Beljanski and his student-turned-colleague, Dr. Michel Plawecki, were able to study at length both the effects of various doses of gamma rays on rabbits and mice as well as certain substances able to protect, to some degree, the organs of irradiated laboratory animals. In particular, he researched how these animals could be shielded from the damage and alterations engendered by radiation-derived toxicity.

Radiation induces body burns inside and outside. In particular it brings on alterations in ribonuclease (the enzymes which primarily break down the RNA that is no longer required in the cell). Ribonuclease also is involved in other important complex chemical reactions in the cell.

In other words, this is part of the chemical structure of your cell that you don’t want altered.

The French army contract stipulated the required study of an American agent for radiation protection labeled as W2721. It was an effective protection, but there were two serious drawbacks: First, W2721 had to be administered intravenously. Second, W2721 had to be stored at a temperature of -328¡F (-200¡C). These constraints, not particularly compatible with the military’s needs, were without a doubt the reason why the product was later abandoned.

For biochemical reasons and because of the legendary resistance to radiation observed to occur in the
Ginkgo biloba
trees following the atomic bombings of Hiroshima and Nagasaki, Beljanski’s attention focused on the leaves of the
Ginkgo
tree.

I have seen
Ginkgo biloba
trees growing in China, Japan, Europe, and in the United States. They live to be over one thousand years old. Growing to a height of 120 feet with a trunk diameter of up to four feet and believed to be living on Earth for 270 million years, the
Ginkgo biloba
tree has been cultivated throughout the world as a result of its resistance to disease. Asian cultures have applied
Ginkgo
seeds as medicinal agents for several centuries. The modern western use of
Ginkgo
has, until now, been limited exclusively to the green leaf of the tree.